- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03270527
RISSCI-1 Blood Cholesterol Response Study (RISSCI-1)
Reading Imperial Surrey Saturated Fat Cholesterol Intervention (RISSCI) Study. RISSCI-1 Blood Cholesterol Response Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The LDL cholesterol-raising effect of saturated fatty acids (SFA) is complex, and highly variable between individuals because of differences in the metabolism of dietary fat and blood cholesterol between people. While these differences in metabolism make it difficult to study how dietary SFA influences LDL-cholesterol in large numbers of people, they can be measured in the laboratory and used as biological markers to distinguish between people who respond well from those who will respond less well to moderate-fat diets, which are lower in SFA.
The main aim of this study is to measure the amount of variation in blood LDL-cholesterol in healthy male volunteers in response to the replacement of SFA with unsaturated fats, and to select LDL-C responders from non-responders for a subsequent metabolic study ('RISSC-2'). Estimate of statistical power and sample size for 'RISSCI-1': A decrease of 0.16 mmol/L (SD 0.54) in our primary outcome of fasting plasma LDL-C between the high- and low-SFA diets, as observed in a previous randomly controlled trial, will require a sample size of 92 participants, at 80% power and 5% significance level. An estimated attrition rate of 15% will increase this sample size to 106 participants. To recruit this sample of participants, we anticipate having to screen 150 volunteers (75 at each site).
Specific objectives:
- Undertake a dietary intervention study to examine the effects of two, 4 week diets that differ in their composition of fatty acids. The first diet ('Diet 1') will contain ~18% of its total energy as saturated fatty acids (SFA), while the second diet ('Diet 2') will contain ~10% of its total energy as SFA. Blood, urine and stool samples taken at the beginning (week 0) and end of Diet 1 (week 4), and end of Diet 2 (week 8), will be analysed to measure blood LDL-cholesterol and other relevant blood, urine and faecal metabolites. The white blood cell buffy coat will also be isolated from the blood samples collected at the baseline visit to enable genotyping of relevant genes involved in the absorption and metabolism of dietary fat.
- To examine the data for evidence of associations between the changes in blood LDL- cholesterol, and the physical and biochemical characteristics of the participants as possible determinants of the variation in serum cholesterol response. This will include measurement of a common genetic polymorphism in APOLIPOPROTEIN E, as an established determinant of variation in blood cholesterol in response to dietary SFA.
- To identify two subgroups of individuals whose blood LDL-cholesterol either responds ('Responders') or show little or no response ('Non-responders') on changing from Diet 1 to Diet 2, for participation in the follow-up study ('RISSCI-2'), which will be conducted at the Universities of Surrey, Reading and Imperial College London. In this follow-up study, the participants will be asked to repeat a similar study protocol as for RISSCI-1, and undergo more detailed measurements to determine how saturated fat is metabolised in the body.
Hypothesis:
In accordance with the variation in blood LDL-cholesterol response, that many studies have reported previously following substitution of dietary saturated with unsaturated fats, the investigators hypothesise that consuming Diet 1 (a high saturated fat diet) for 4 weeks followed by diet 2 (a low saturated fat/high unsaturated fat diet) for a further 4 weeks, will: 1) produce a variable distribution of responses in LDL-cholesterol that will enable the study of associations between the participants' baseline characteristics as possible determinants of the observed variation in blood LDL-cholesterol response, and 2) identify two distinct subgroups of individuals who either respond or show little or no response in their blood LDL- cholesterol. These distinct groups will be defined by the top and bottom ~10% of change in the concentration of blood LDL-cholesterol.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Berkshire
-
Reading, Berkshire, United Kingdom, RG6 6AP
- Department of Food and Nutritional Sciences, University of Reading
-
-
Surrey
-
Guildford, Surrey, United Kingdom, GU2 7WG
- Department of Nutritional Sciences, University of Surrey
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI of 19-32 kg/m2
- Fasting serum total cholesterol < 7.5 mmol/l and triacylglycerol < 2.3 mmol/l
Exclusion Criteria:
- Smokers
- Medical history of myocardial ischemia or stroke in the past 12 months;
- Diabetes (defined as fasting glucose > 7.0 mmol/l) or other endocrine disorders; kidney, liver, pancreas or gastrointestinal disorders
- Hypertension (blood pressure > 140/90 mmHg),
- Cancer
- Medication for hyperlipidaemia (e.g. statins), hypertension, inflammation or prescribed antibiotics within the last three months
- Drinking in excess of 14 units of alcohol per week,
- Anaemia (<130 g/L haemoglobin), or planning on a weight-reducing regime
- Taking any dietary supplements known to influence lipids/gut microbiota (eg. plant stanols, fish oil, phytochemicals, natural laxatives, probiotics and prebiotics)
- Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High SFA diet to low SFA diet
Participants will undergo, sequentially, a high SFA diet (Diet 1) followed by a low SFA diet (Diet 2) for 4 weeks each.
Study visits will occur before and after each dietary intervention period.
To comply with current UK dietary recommendations, Diets 1 and 2 will both contain ~35% energy from total fat.
These diets will be consumed within the homes of free-living participants, by the substitution of ~40g of habitual fat, with either SFA-rich or mono/poly-unsaturated fatty acid-rich (MUFA/PUFA) cooking oils, spreads and snack foods, while maintaining their habitual diet (consistent intake of protein and carbohydrates, including dietary fibre).
This will be achieved using a dietary exchange model developed and peer-reviewed for a previous dietary intervention study ('DIVAS') at the University of Reading, U.K.
|
'Diet 1' will contain ~18% of its total energy as SFA .
'Diet 2' will contain ~10% of its total energy as SFA.
The SFA-replacement fats will be mixture of PUFA/MUFA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in fasting total cholesterol (consisting of LDL-cholesterol and HDL) concentrations
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting triacylglycerol
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
HDL immune functions
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
HDL anti-inflammatory and anti-oxidant (PON-1) properties
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
HDL capacity to promote cholesterol efflux (ex-vivo)
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Fasting insulin, glucose
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Adhesion molecules, markers of vascular function
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Inflammatory markers & adipokines
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
LDL-R gene expression
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Other relevant genes involved in the absorption and metabolism of dietary fat
Time Frame: Baseline
|
Polymorphic genes with potential influence on the serum LDL response to dietary saturated fat, e.g.: ATP-binding cassette proteins (cholesterol efflux proteins) ABCG5 (e.g.
C1950G) ABCG8 (e.g.
D19H, C1895T), functional polymorphisms in the farnesoid X receptor (FXR) and bile acid transporters (e.g.
solute carrier organics anion 1B1).
Fatty acid desaturases (FADS1 and FADS2).
The patatin-like phospholipase domain-containing protein (PNPLA3) (e.g.
rs738409 C/G), eNOS.
Lipid/cholesterol homeostasis: serum apolipoprotein genes: APOE (ε2,ε3,ε4 e.g.
rs429358 and rs7412), APOA-I (e.g.
-75G/A), APOA4 (e.g.
360-2), APOA5 (e.g.
-113/T>:c), APOCIII, APOB (e.g.
-516C/T).
Lipase genes: (e.g.
LPL, HL, MGLL).
Lipoprotein receptor genes (e.g.
pvu11 in the LDL receptor), lipid transfer proteins (e.g.
CETP e.g Taq1B, MTP), and other polymorphic genes related to the absorption and metabolism of dietary fat and regulation of lipid/cholesterol homeostasis.
|
Baseline
|
Metabolomic analysis for the determination of the low molecular weight metabolite profiles in the biological fluids
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Analyses conducted by Imperial College London
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Changes in faecal bacterial population
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Weight
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
BMI will also be calculated (kg/ height in m^2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Fat mass
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Fat free mass
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Waist circumference
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Hip circumference
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Blood pressure
Time Frame: Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
|
Fasting vascular stiffness
Time Frame: baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Measured via pulse wave assessment using the Mobil-O-graph device.
|
baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Genotyping for apolipoprotein E to determine the impact of this genotype on changes in the primary and secondary outcome measurements in response to dietary fat intake
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julie Lovegrove, PhD, University of Reading
- Principal Investigator: Bruce Griffin, PhD, University of Surrey
Publications and helpful links
General Publications
- Vafeiadou K, Weech M, Altowaijri H, Todd S, Yaqoob P, Jackson KG, Lovegrove JA. Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. Am J Clin Nutr. 2015 Jul;102(1):40-8. doi: 10.3945/ajcn.114.097089. Epub 2015 May 27.
- Sellem L, Antoni R, Koutsos A, Ozen E, Wong G, Ayyad H, Weech M, Schulze MB, Wernitz A, Fielding BA, Robertson MD, Jackson KG, Griffin BA, Lovegrove JA. Impact of a food-based dietary fat exchange model for replacing dietary saturated with unsaturated fatty acids in healthy men on plasma phospholipids fatty acid profiles and dietary patterns. Eur J Nutr. 2022 Oct;61(7):3669-3684. doi: 10.1007/s00394-022-02910-2. Epub 2022 Jun 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RN0307A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on High SFA diet (Diet 1)
-
Maastricht University Medical CenterUnilever R&DCompletedObesity | Diet, Healthy | Fatty Liver, NonalcoholicNetherlands
-
Rutgers, The State University of New JerseyCompleted
-
University of ReadingCompleted
-
Phoenix VA Health Care SystemUnknown
-
Chinese Academy of SciencesCompletedHealthy and Overweight/ Obesity MalesChina
-
University of OsloThe Research Council of Norway; University of OxfordCompleted
-
Uppsala UniversitySwedish Council for Working Life and Social ResearchCompletedObesity | Diabetes | Fatty Liver | Insulin ResistanceSweden
-
Oregon Health and Science UniversityCompletedTrifunctional Protein Deficiency | Carnitine Palmitoyltransferase 2 Deficiency | Very Long-chain Acyl-CoA Dehydrogenase Deficiency | Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
-
National University of SingaporeActive, not recruitingPersonalized NutritionSingapore
-
Wageningen UniversityTop Institute Food and NutritionCompletedIdentify New Biomarkers in Blood or Urine After Consumption of Meat Protein, Dairy Protein and Grain Protein in Healthy Subjects.Netherlands